Research programme: phosphatidylinositol 3-kinase delta inhibitors - Merck & Co

Drug Profile

Research programme: phosphatidylinositol 3-kinase delta inhibitors - Merck & Co

Alternative Names: PI3K-δ inhibitors; XL-499

Latest Information Update: 20 Oct 2015

Price : $50

At a glance

  • Originator Exelixis
  • Developer Merck & Co
  • Class Small molecules
  • Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer; Inflammation

Most Recent Events

  • 20 Oct 2015 Preclinical development is ongoing for Inflammation and Cancer in USA
  • 21 Dec 2011 Exelixis grants Merck & Co an exclusive worldwide license to its phophatidylinositol 3-kinase delta inhibitors research and development programme
  • 21 Dec 2011 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top